# US 8,685,898 B2 · Adaptive immunity profiling and methods for generation of monoclonal antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,685,898 B2
- Document ID: US8685898B2
- Status: Granted
- Kind: B2
- Application number: 13/144,645
- Filed: 2010-01-15
- Published: 2012-01-19
- Granted: 2014-04-01
- Earliest claimed: 2009-01-15
- Assignees: Imdaptive Inc.
- Applicants: Steven R. Wiley
- Inventors: Steven R. Wiley
- Web page: https://patentgrep.com/patent/US8685898B2

## CPC

- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C07K 16/205: {Plasmodium}
- C12N 15/1034: {Isolating an individual clone by screening libraries}
- C40B 50/06: Biochemical methods, e.g. using enzymes or whole viable microorganisms
- C12N 15/1072: {Differential gene expression library synthesis, e.g. subtracted libraries, differential screening}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)

## Abstract

Methods are provided for producing monoclonal antibody candidates using adaptive immunity profiling. In some aspects, the method provides for the use of massively parallel signature sequencing.

## Claims

### Claim 1

A method, comprising:
generating a first cDNA sequence library comprising a first set of target antibody cDNA sequences, said first set of target antibody cDNA sequences obtained from a first sample comprising lymphocytes of a host subject that has not been immunized with an antigen and each of said first set of target antibody cDNA sequences comprising an immunoglobulin (Ig) heavy chain variable domain sequence,
wherein generating said first cDNA sequence library comprises amplifying said first set of target cDNA sequences and sequencing said amplified first set of target cDNA sequences;
generating a second cDNA sequence library comprising a second set of target antibody cDNA sequences, said second set of target antibody cDNA sequences obtained from a second sample comprising lymphocytes of said host subject after being immunized with said antigen and each of said second set of target antibody cDNA sequences comprising an immunoglobulin (Ig) heavy chain variable domain sequence,
wherein generating said second cDNA sequence library comprises amplifying said second set of target cDNA sequences and sequencing said amplified second set of target cDNA sequences;
analyzing the frequencies of occurrence of each of said first and second set of target antibody cDNA sequences;
identifying candidate antibody cDNA sequences that have a statistically significantly higher frequency of occurrence in said second set of target antibody cDNA sequences compared to a frequency of occurrence of said first set of target antibody cDNA sequences;
selecting said candidate antibody cDNA sequences for generating monoclonal antibodies; and
expressing said candidate antibody cDNA sequences to produce a plurality of candidate monoclonal antibodies.

### Claim 2 (depends on 1)

The method of claim 1, wherein the lymphocytes comprise isolated B cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein expressing said candidate antibody cDNA sequences to produce a plurality of candidate monoclonal antibodies comprises subcloning said candidate antibody sequences with a light chain variable domain sequence and an Ig framework.

### Claim 4 (depends on 3)

The method of claim 3, wherein the Ig framework is a human Ig framework.

### Claim 5 (depends on 3)

The method of claim 3, further comprising assaying the candidate monoclonal antibodies for affinity to the antigen.

### Claim 6 (depends on 3)

The method of claim 3, further comprising subjecting the plurality of candidate monoclonal antibodies to positive selection to identify one or more high affinity monoclonal antibodies.

### Claim 7 (depends on 6)

The method of claim 6, wherein subjecting the plurality of candidate monoclonal antibodies to positive selection comprises contacting the plurality of candidate monoclonal antibodies to the antigen bound to a substrate and isolating bound antibodies from unbound antibodies.

### Claim 8 (depends on 6)

The method of claim 6, wherein the candidate monoclonal antibodies bind to an antigen with an affinity of at least 1×1010 liter/mole, measured as an association constant (Kaff).

### Claim 9 (depends on 6)

The method of claim 6, further comprising sequencing the high affinity monoclonal antibodies.

### Claim 10 (depends on 1)

The method of claim 1, wherein the frequencies of occurrence of said first and second set of target antibody cDNA sequences are analyzed using a bioinformatics software algorithm.

### Claim 11 (depends on 1)

The method of claim 1, wherein the first and second set of target antibody cDNA sequences of said first and second cDNA sequence libraries are sequenced by massively parallel signature sequencing (MPSS).

### Claim 12 (depends on 1)

The method of claim 1, wherein the host subject is an experimental animal.

### Claim 13 (depends on 1)

The method of claim 1, wherein the host subject is a transgenic animal expressing human antibodies.

### Claim 14 (depends on 1)

The method of claim 1, wherein the host subject is a human.

### Claim 15 (depends on 1)

The method of claim 1, wherein generating said first or second cDNA sequence library comprises:
i) isolating lymphocytes from the host subject;
ii) isolating mRNA from the lymphocytes; and
iii) reverse transcribing the mRNA to cDNA.
